Abstract
Background: Cholangiocarcinoma (CCA) is a rare cancer type that formed by the transformation of bile duct epithelial cells. Its survival rate is low and there is no clear standard treatment strategies in clinical terms. Although regorafenib has been announced as a secondary treatment option for patients with CCA. However, the detailed molecular mechanism is still unknown.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
